Stage IV Cutaneous Melanoma AJCC v6 and v7 Recruiting Phase 3 Trials for Trametinib (DB08911)

IndicationStatusPhase
DBCOND0091050 (Stage IV Cutaneous Melanoma AJCC v6 and v7)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02224781Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaTreatment